



# The Illinois Medical Bulletin



## The Causal Relationship Between Tobacco Smoking and the Pathogenesis of Chronic Obstructive Pulmonary Disease: A Review of Foundational Evidence

<sup>1</sup>A. Bose, <sup>2</sup>A. Bourland

<sup>1,2</sup> University of Illinois College of Medicine

Corresponding Email : [bosemd828772@gmail.com](mailto:bosemd828772@gmail.com)

### Article History :

Received date : 2014/10/12  
Revised date : 2014/11/28  
Accepted date : 2014/12/09  
Published date : 2015/01/13



**Copyright:** © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

---

### ABSTRACT

---

**Introduction:** Chronic Obstructive Pulmonary Disease (COPD), a major cause of chronic morbidity and mortality worldwide, is characterised by progressive and poorly reversible airflow limitation. While other risk factors exist, tobacco smoking has been identified as the predominant etiological agent. This review aims to synthesise the foundational epidemiological and mechanistic literature published before 2010 that established the definitive causal link between smoking and the development of COPD.

**Literature Review:** Landmark longitudinal studies provided irrefutable epidemiological evidence, demonstrating that smoking causes a dose-dependent, accelerated decline in lung function over time. The core pathogenic mechanisms were elucidated, centering on two concepts: a protease-antiprotease imbalance, where smoke-induced inflammation leads to enzymatic destruction of the lung parenchyma causing emphysema; and a chronic inflammatory response in the small airways, leading to fibrosis and obstructive bronchiolitis.

Oxidative stress, induced by the high concentration of oxidants in cigarette smoke, was identified as a key process that amplifies inflammation and tissue damage. Crucially, large-scale clinical trials, such as the Lung Health Study, provided definitive proof that smoking cessation was the only intervention capable of slowing the progressive loss of lung function.

**Conclusion:** The extensive body of evidence reviewed confirms that COPD is overwhelmingly a disease caused by tobacco smoking. The causal pathway, from smoke exposure to airflow limitation, is supported by robust epidemiological data and a well-defined understanding of the underlying inflammatory and destructive processes.

**Keywords:** COPD, Tobacco Smoking, Emphysema, Chronic Bronchitis, Smoking Cessation.

---

## **INTRODUCTION**

---

Chronic Obstructive Pulmonary Disease (COPD) represents a major global health challenge, consistently ranking among the leading causes of disability and death. The disease is defined by persistent airflow limitation that is typically progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. While occupational exposures and genetic factors, such as alpha-1 antitrypsin deficiency, can contribute to its development, the vast majority of the disease burden is attributable to a single, modifiable environmental factor: tobacco smoking.

The clinical observation linking chronic cough and breathlessness to long-term smoking dates back centuries. However, it was the scientific and epidemiological research of the 20th and early 21st centuries that systematically dissected this relationship, moving from simple association to an established causal pathway. This literature review aims to explore the foundational body of work published before 2010 that cemented the role of tobacco smoking as the principal cause of COPD, examining the epidemiological evidence, the core pathogenic mechanisms, and the impact of smoking cessation.

---

## **LITERATURE REVIEW**

---

The evidence establishing smoking as the cause of COPD is built upon decades of converging research in epidemiology, pathology, and clinical medicine.

The epidemiological foundation is exceptionally strong. The landmark longitudinal study by Fletcher and Peto (1977) was pivotal, following working men for over eight years and

meticulously documenting their lung function decline over time. They demonstrated that while lung function (measured as Forced Expiratory Volume in 1 second, or FEV1) naturally declines with age, smokers experience a much steeper, dose-dependent decline. They also showed that smoking cessation could return the rate of decline to that of a non-smoker, although the lung function already lost was irrecoverable. This work established the natural history of the disease and the critical window for intervention. Later, large-scale clinical trials like the Lung Health Study further confirmed this, showing definitively that a smoking cessation intervention was successful in slowing the rate of FEV1 decline in individuals with mild COPD (Anthonisen et al., 1994).

The pathogenic mechanisms by which cigarette smoke destroys the lung were a major focus of research. A leading concept that gained prominence was the "protease-antiprotease hypothesis" (Snider, 1986). This theory posits that cigarette smoke incites a massive inflammatory response in the lung, recruiting vast numbers of neutrophils and alveolar macrophages. These cells release powerful proteolytic enzymes, such as neutrophil elastase, which are capable of degrading elastin and other connective tissue components of the alveolar walls. In a healthy lung, these proteases are held in check by a screen of antiproteases, primarily alpha-1 antitrypsin. Cigarette smoke disrupts this delicate balance in two ways: it increases the burden of proteases and it deactivates the protective antiproteases through oxidation, tipping the balance heavily towards tissue destruction and the development of emphysema (Barnes, 2000).

In parallel to the destruction of the lung parenchyma (emphysema), smoking also induces profound changes in the airways, causing the chronic bronchitis and obstructive bronchiolitis components of COPD. Cigarette smoke acts as a potent irritant, leading to hypertrophy of submucosal glands, goblet cell metaplasia, and excessive mucus production. More importantly, it drives a chronic inflammatory process in the small peripheral airways, characterized by infiltration of macrophages, neutrophils, and CD8<sup>+</sup> T-lymphocytes. This chronic inflammation leads to peribronchiolar fibrosis and narrowing of the small airways, a key contributor to the progressive airflow limitation (Pauwels et al., 2001). Oxidative stress, resulting from the immense load of free radicals and oxidants in tobacco smoke, was identified as a unifying mechanism that contributes to both direct tissue injury and the amplification of the inflammatory and protease-mediated damage (Barnes, 2000).

---

## **CONCLUSION**

---

The foundational scientific and clinical literature published before 2010 provides unequivocal and overwhelming evidence that tobacco smoking is the principal cause of Chronic Obstructive Pulmonary Disease. Landmark epidemiological studies rigorously documented the accelerated loss of lung function in smokers and established a clear dose-response relationship. The pathogenic mechanisms were clearly elucidated, demonstrating that smoke-induced chronic inflammation drives both the enzymatic destruction of the lung parenchyma, leading to emphysema, and the fibrotic narrowing of small airways, causing irreversible airflow obstruction.

Crucially, this body of research also proved that the disease trajectory could be altered. Major clinical trials confirmed that smoking cessation is the single most effective intervention to slow the progression of COPD, reinforcing the causal link and establishing the cornerstone of management. The comprehensive evidence reviewed confirms that the understanding of COPD as an inflammatory disease caused by smoking was firmly established, forming the immutable foundation for all subsequent research, public health policy, and clinical guidelines related to the disease.

---

## **REFERENCES**

---

Anthonisen, N.R., Connett, J.E., Kiley, J.P., Altose, M.D., Bailey, W.C., Buist, A.S., Conway, W.A., Jr., Enright, P.L., Kanner, R.E., O'Hara, P. and Owens, G.R. (1994) 'Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study', *JAMA*, 272(19), pp. 1497-1505.

Barnes, P.J. (2000) 'Chronic obstructive pulmonary disease', *New England Journal of Medicine*, 343(4), pp. 269-280.

Fletcher, C. and Peto, R. (1977) 'The natural history of chronic airflow obstruction', *British Medical Journal*, 1(6077), pp. 1645-1648.

Pauwels, R.A., Buist, A.S., Calverley, P.M., Jenkins, C.R. and Hurd, S.S. (2001) 'Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary', *American Journal of Respiratory and Critical Care Medicine*, 163(5), pp. 1256-1276.

Snider, G.L. (1986) 'Experimental studies on emphysema and chronic bronchial injury',  
*European Journal of Respiratory Diseases. Supplement*, 146, pp. 17-35.